Maravai LifeSciences (MRVI)
(Real Time Quote from BATS)
$8.92 USD
+0.32 (3.72%)
Updated Jul 12, 2024 12:22 PM ET
5-Strong Sell of 5 5
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MRVI 8.92 +0.32(3.72%)
Will MRVI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRVI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRVI
Maravai (MRVI) Advances in RNA Research With New Collaboration
Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?
MRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
PetIQ (PETQ) Moves 5.7% Higher: Will This Strength Last?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Other News for MRVI
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
RBC Capital Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Applied DNA, Alphazyme conclude Linea RNAP manufacturing scale-up project
Applied DNA, Alphazyme conclude Linea RNAP manufacturing scale-up project